Evidence map›Paper›PMID 29370237›Full record

ArticlePloS one2018

Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS.

Sabrina Ruppenthal, Helga Kleiner, Florian Nolte, Alice Fabarius, Wolf-Karsten Hofmann, Daniel Nowak, Wolfgang Seifarth

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Systemic arterial hypertension but not IGF-I treatment stimulates cardiomyocyte enlargement in neonatal lambs.American journal of physiology. Regulatory, integrative and comparative physiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sabrina RuppenthalDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0002-8700-9432
Helga KleinerDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Florian NolteDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Daniel NowakDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolfgang SeifarthDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ESPL1/separase, a cysteine endopeptidase, is a key player in centrosome duplication and mitotic sister chromatid separation. Aberrant expression and/or altered separase proteolytic activity are associated with centrosome amplification, aneuploidy, tumorigenesis and disease progression. Since centrosome alterations are a common and early detectable feature in patients with myelodysplastic syndrome (MDS) and cytogenetic aberrations play an important role in disease risk stratification, we examined separase activity on single cell level in 67 bone marrow samples obtained from patients with MDS, secondary acute myeloid leukemia (sAML), de novo acute myeloid leukemia (AML) and healthy controls by a flow cytometric separase activity assay. The separase activity distribution (SAD) value, a calculated measure for the occurrence of cells with prominent separase activity within the analyzed sample, was tested for correlation with the centrosome, karyotype and gene mutation status. We found higher SAD values in bone marrow cells of sAML patients than in corresponding cells of MDS patients. This concurred with an increased incidence of aberrant centrosome phenotypes in sAML vs. MDS samples. No correlation was found between SAD values and the karyotype/gene mutation status. During follow-up of four MDS patients we observed increasing SAD values after transformation to sAML, in two patients SAD values decreased during azacitidine therapy. Cell culture experiments employing MDS-L cells as an in vitro model of MDS revealed that treatment with rigosertib, a PLK1 inhibitor and therapeutic drug known to induce G2/M arrest, results in decreased SAD values. In conclusion, the appearance of cells with unusual high separase activity levels, as indicated by increased SAD values, concurs with the transformation of MDS to sAML and may reflect separase dysregulation potentially contributing to clonal evolution during MDS progression. Separase activity measurement may therefore be useful as a novel additional molecular marker for disease monitoring.

Indexed as

CentrosomeChromosome AberrationsAdultAgedAged, 80 and overCase-Control StudiesCell CycleFemaleHumansKaryotypingMaleMiddle AgedMutationMyelodysplastic SyndromesPhenotypeSeparaseSeparase

Identifiers

PMID29370237
PMCPMC5784974
OpenAlexW2792354226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.